|
|
| (6 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticagrelor#Contraindications]] |
| {{Ticagrelor}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Contraindication==
| |
| ====History of Intracranial Hemorrhage====
| |
| BRILINTA is contraindicated in patients with a history of [[intracranial hemorrhage]] (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14)].
| |
| | |
| ====Active Bleeding====
| |
| BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or [[intracranial hemorrhage]] [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
| |
| | |
| ====Severe Hepatic Impairment====
| |
| BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of [[coagulation proteins]] [see Clinical Pharmacology (12.3)].
| |
| | |
| ====Hypersensitivity====
| |
| BRILINTA is contraindicated in patients with hypersensitivity (e.g. [[angioedema]]) to ticagrelor or any component of the product [see Adverse Reactions (6.2)]. <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Antithrombotics}}
| |
| | |
| [[Category:ADP receptor inhibitors]]
| |
| [[Category:Triazolopyrimidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Alcohols]]
| |
| [[Category:AstraZeneca]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |